Edesa Biotech has signed an agreement granting Kyorin Pharmaceutical rights to develop and sell paridiprubart in Japan, a deal worth up to $140M plus royalties for an antibody still in phase 3 testing.
The Ontario-based company disclosed the arrangement on November 9. Paridiprubart is being developed for acute respiratory distress syndrome, an inflammatory lung condition with few effective options.
What Kyorin is buying
Kyorin gains exclusive Japanese commercial and development rights to the antibody. Edesa keeps the rest of the world and receives a tiered payment structure tied to regulatory and sales milestones on top of the royalty stream.
The agreement hands the program a partner with an established Japanese respiratory and hospital sales presence, sparing Edesa the cost of building that footprint itself while it funds a late-stage trial at home.
A crowded late-stage race
ARDS has drawn growing interest from drugmakers after years of failed trials. Paridiprubart targets the innate immune signaling that drives the runaway lung inflammation characteristic of severe cases.
Phase 3 remains the hardest test. The condition’s heterogeneity, wide-ranging causes from pneumonia to sepsis, and high mortality have tripped up multiple candidates, and Edesa has not yet reported pivotal data.
For Kyorin, the deal adds a critical care asset to a portfolio weighted toward infectious disease and respiratory medicine. For Edesa, the upfront cash extends a runway that matters more than the milestone headline, since the back-loaded portion depends on outcomes nobody can promise yet.
